Literature DB >> 35379081

The global lung function initiative 2021 (GLI-2021) norms provide mixed results for static lung volumes (SLVs) in Algerian adults.

Abdelbassat Ketfi1, Helmi Ben Saad2,3,4.   

Abstract

The validity of the GLI-2021 norms for SLVs in healthy Algerian adults has not been assessed. To ascertain how well do the GLI-2021 norms fit to contemporary SLVs data in Algerian adults. This was a cross-sectional study involving 481 (n = 242 females) healthy non-smoking adults recruited from the Algiers general population. All participants underwent a clinical examination and a plethysmography. Z-scores for slow vital capacity (SVC), functional residual capacity (FRC), residual volume (RV), total lung capacity (TLC), expiratory reserve volume (ERV), inspiratory capacity (IC), and RV/TLC were calculated. The mean difference between the determined and the predicted values (∆value) of SLVs were calculated. The GLI-2021 norms would be considered as reflective of contemporary Algerian SLVs if the total sample mean z-scores were in the normal range (ie; -0.5 to +0.5). The participants' means ± SDs of age and height were 46.4 ± 16.4 years and 166 ± 10 cm, respectively. The determined SLVs were significantly different from those predicted (∆values means ± SDs were -170 ± 470 ml for IC, -100 ± 490 ml for SVC, 170 ± 400 ml for ERV, 240 ± 620 ml for TLC, 370 ± 340 ml for RV, 480 ± 480 ml for FRC, and 5.28 ± 4.38% for RV/TLC). The means ± SDs z-scores for IC, SVC, ERV, and TLC were in the normal range (-0.29 ± 0.88, -0.17 ± 0.94, 0.29 ± 0.77, and 0.35 ± 0.86, respectively), but those of RV, FRC, and RV/TLC were out of the normal range (0.74 ± 0.66, 0.75 ± 0.72, and 0.83 ± 0.75, respectively). In healthy Algerian adults, the GLI-2021 norms fit well to SVC, TLC, ERV, and IC, but they do not fit to FRC, RV, and RV/TLC.

Entities:  

Keywords:  Algeria; GLI-2021; lung function test; reference values; static lung volumes; validation

Mesh:

Year:  2022        PMID: 35379081      PMCID: PMC8986198          DOI: 10.1080/19932820.2022.2059893

Source DB:  PubMed          Journal:  Libyan J Med        ISSN: 1819-6357            Impact factor:   1.657


Introduction

According to scholarly societies [1], spirometric and static lung volumes (SLVs) norms should be derived from measurements carried out within a representative sample of the general population, i.e. an adapted population of ‘healthy/normal’ individuals possessing similar anthropometric, ethnic, and socio-economic conditions as the patients tested [1-3]. Therefore, it is recommended to use norms that fit the population to be explored [1]. Nowadays, lung function parameters (LFPs) are habitually reported as percentage predicted where predicted data are derived from a healthy non-smoking population [1,4]. Nevertheless, it appears that the use of percentage predicted leads to an age bias [5], which can be avoided by the use of sex, age, height, and ethnicity-specific z-scores [6,7]. The z-score indicates how many standard deviations (SDs) a measurement is from its predicted value, with 90% of healthy individuals having a z-score between +1.645 and −1.645 [6,7]. Unlike percentage predicted, z-score is free of bias related to age, height, sex, and ethnic group, and it is accordingly suitable for defining lower- and upper limits of normal (LLN and ULN, respectively). They also simplify the uniform interpretation of LFPs [6,8-10]. In Algeria, spirometric and SLVs norms were developed for adults living in Constantine, an Eastern region of Algeria [11]. For several reasons (eg; environmental factors relating to altitude, air pollution and humidity, in addition to anthropometric disparities), the aforementioned norms were judged inapplicable to Northern Algerian adult residents [12]. In 2018, global lung function initiative multi-ethnic spirometric norms (GLI-2012) [6] were found to be applicable to a representative sample of the Algiers region [10]. However, the GLI-2012 norms only concern spirometric data [10]. Currently, physicians do not have any norms for SLVs whose applicability is verified on the general Algerian population. In 2021, the GLI Task Force released SLVs norms (GLI-2021) including 7190 observations from healthy individuals between the ages of 5 and 80 years [7]. The observations were collected from 17 centers in 11 countries, including one in Tunisia who contributed by SLVs values from 615 Tunisians (8.55% of the total data)) [7]. The GLI-2021 sex-specific norms [7], including height and age, were developed for total lung capacity (TLC), functional residual capacity (FRC), residual volume (RV), inspiratory capacity (IC), slow vital capacity (SVC), expiratory reserve volume (ERV), and RV/TLC. As done during the genesis of the GLI-2012 spirometric norms [6], the LMS [lambda, mu, and sigma] method was used and the generalized additive models of location shape and scale were applied [6,13]. External validation of the GLI-2021 norms is recommended [7], and further evaluations of their applicability to other parts of the world are required in order to verify their appropriateness in these areas [7]. In Algeria, the GLI-2021 norms [7] will shortly be implemented by manufacturers of plethysmography devices, and will therefore replace the applied local norms [11]. Thus, verifying their applicability to the Algerian population seems to be crucial for care activities and research, and is urgently required. Hitherto, there is no publication evaluating the validity of the GLI-2021 norms [7] in Algerian adults. Since the GLI-2021 norms [7] may be unsuitable for use in Algerian adult population, it is essential that physicians be aware of the potential consequences of adopting these norms for clinical decision-making [7]. Taking into account the above points, the aim of this study was to evaluate if the GLI-2021 norms [7] are applicable to an adult Algerian population.

Population and methods

This study is part of a project involving four parts largely described in Figure 1. The first part [10] aimed at testing the validity of the GLI-2012 norms [6]. The second part [12] aimed at testing the validity of the Eastern Algeria plethysmographic norms [11]. The third part [14] aimed at evaluating the impact of parity on females’ plethysmographic data. The fourth part constitutes the topic of this study. The final total population included 481 healthy adults (50.3% males) living in Algiers (Figure 1). Figure 2 exposes the present study flow-chart.
Figure 1.

Description of the fourth parts of the project.

Figure 2.

Present study flow-chart.

Description of the fourth parts of the project. Present study flow-chart. Distribution of the 481 participants according to sex, age and height ranges.

Study design

A cross-sectional study was performed at the Department of Pneumology, Phthisiology, and Allergology in Rouiba Hospital, Algiers, Algeria. The study was conducted in compliance with Helsinki ‘Ethical principles for medical research involving Human subjects’. Rouiba Hospital (Algiers) Medical Advice and Ethics Commission approved the study (approval number: 0601/2014). Written informed consent was obtained from all participants.

Study population

The target population consisted of a group of healthy Algerian adults. Participants were selected by convenience sampling from the acquaintances of patients hospitalized at the above department during, for example, the hospital visiting time. The inclusion, non-inclusion, and exclusion criteria, which were previously described [10,12,14], are reported in Figure 2. In this study, only healthy adults aged ≥18 years with technically acceptable and repeatable plethysmographic/spirometric maneuvers were included. In order to meet the GLI-2021 norms age limits, adults over 80 years of age were excluded from the final statistical analysis [7].

Medical and anthropometric data

Medical data were collected using a simplified and modified medical questionnaire [15]. Age (accuracy to 0.1 years) was calculated, and standing height and weight were measured. Depending on the calculated body mass index (BMI, kg/m2), participants were classified as: underweight (BMI < 18.5 kg/m2), normal weight (BMI: 18.5 to 24.9 kg/m2), overweight (BMI: 25.0 to 29.9 kg/m2), and obese (BMI ≥ 30.0 kg/m2) [16]. Obesity was classified as stage-1 (BMI: 30.0 to 34.9.0 kg/m2), stage-2 (BMI: 35.0 to 39.9.0 kg/m2), and stage-3 (BMI > 40.0 kg/m2).

Plethysmographic and spirometric measurements

One qualified person (AK in the authors’ list) performed all the plethysmographic/spiromtric tests in the morning. All measurements were performed with a body plethysmograph (Body-box 5500, MediSoft, Belgium), following carefully the international guidelines [8,10-12,14,17,18] in the following order: FRC maneuver and spirometry maneuver. The spirometer was calibrated daily with a 3-L syringe. The plethysmography was calibrated daily according to manufacturer’s instructions. The plethysmography was performed, after a resting period of 10–15 minutes, in a seated position, back straight, with a nose clip. The maneuvers to be performed were explained and their demonstrations supported these explanations. Inspiratory and expiratory maneuvers were forced, maximal, performed without hesitation, and continued until the RV. The plethysmographic technique followed the succeeding steps [18]: i) The procedure was explained in detail to participants; ii) The plethysmograph door was closed and time was allotted for thermal transients to stabilize and patients to relax; iii) Participants were instructed to attach the mouthpiece and breathe quietly until they achieved stable end-expiration; iv) When participants were at or near FRC, the shutter was closed at end-expiration for 2–3 s, and they were instructed to perform a series of gentle pants at a frequency of 0.5–1.0 Hz; v) After a series of 3–5 technically satisfactory panting maneuvers was recorded, the shutter opened and participants performed an ERV maneuver followed by an SVC maneuver. The repeatability and acceptability criteria were respected for plethysmography and spirometry [17,18]. Regarding the FRC repeatability, at least three values were obtained and the difference between the highest and the lowest FRC values divided by the mean was ≤ 0.05 [18]. The FRC average value was selected [18]. For the forced vital capacity (FVC) manoeuvres, at least three repeatable FVC measurements were obtained [17]. FVC and forced expiratory volume in 1 second (FEV1), the best two tests out of the three selected ones, did not differ by more than 0.150 L (if FVC ≥ 1 L), or 0.100 L (if FVC < 1 L). The highest FVC and FEV1 were computed even though the two data did not come from the same flow-volume curve [17]. Three spirometric data were measured [FEV1, FVC, and forced expiratory flow at 25–75% of FVC (FEF25-75%], and FEV1/FVC ratio was calculated. The use of accompanying spirometry maneuvers allowed the measurement of some dynamic lung volumes (; SVC, ERV, and IC), and when combined with FRC, it allowed the calculation of additional SLVs [; RV (= FRC – ERV), TLC (= SVC + RV)], and the RV/TLC ratio (%) [7]. More details related to the collected data during the spirometric/plethysmographic tests are recently reported in an Editorial aiming to review the current use of GLI-2012 [6] and GLI-2021 [7] in Great Arab Maghreb countries and steps required to improve their utilization [19]. An online software for the GLI-2012 and the GLI-2021 [6,7] norms was used [20]. An Excel file including the mandatory and optional input values for our calculator of interest (ie; age, height, sex, ethnicity, FEV1, FVC, FEF25-75%, FRC, TLC, RV, ERV, IC, and SVC) was uploaded on the calculator page. The software performed the calculation, and the results were returned automatically. Height-, age-, and sex-specific z-scores for spirometric and SLVs parameters were calculated using the GLI-2012 spirometric norms for Caucasians [6], and GLI-2021 norms [7], respectively. For each parameter, the software calculated several outcomes (ie; predicted value, LLN, ULN, and z-score). SLVs were divided into two categories: low (i.e. SLV z-score < −1.645) and high (SLV z-scores > + 1.645) volume [1,2,7]. For each SLV, a delta volume (∆SLV = determined value minus predicted value) was calculated.

Statistical analysis

The distribution of quantitative variables was normal and the results were expressed by their means ± SDs and 95% confidence interval. The corpulence status results and sex were expressed as numbers (%). The two-sided chi-square test was used to compare percentages. The Student t-test was used to compare the anthropometric data and LFPs of males and females. The Wilcoxon test was used to compare the determined LFPs with those predicted from the GLI norms for spirometry and SLVs [6,7]. As proposed by Bland and Altman [21], limits of agreement (ie; mean difference between measured and predicted value±1.96 SD) were used for comparison of measured SLVs (i.e. SVC, FRC, RV, TLC, ERV, and IC) with predicted values calculated from the GLI-2021 norms [7], with individual difference (measured value minus predicted value) plotted against the corresponding mean value. The correlations between mean differences and mean values were evaluated by Pearson’s product-moment correlation ‘r’. The main judgment criterion related to the applicability or not of the GLI-2021 norms [7] is the mean value of the total sample z-score of each SLV. The expected z-scores of the tested population (ie; determined SLV value) would have a mean of ‘> 0’ and a SD of ‘> 1’, and would therefore be considered ‘statistically’ significant [6]. As previously done [6,8-10], and according to a consensus established by the GLI Task Force, a z-score out of the normal range (ie; < −0.5 or > + 0.5) was arbitrarily considered ‘clinically’ significant [22]. Two additional secondary criteria are in favour of the validity of the GLI-2021 norms [7] in the total sample: i) the absence of statistically (i.e. p < 0.05) [12] and clinically (i.e. ∆SLV > 0.200 L for SVC [1,23,24], or > 0.300 L for FRC, TLC, and RV [25,26]) significant differences between the determined and the predicted SLVs; and ii) less than 5% of participants have abnormal SLVs (i.e. low SVC or IC, or high FRC, TLC, RV, or RV/TLC) [6,12]. The associations between z-scores, and both sex and anthropometric data were evaluated, respectively, by Student t-test and Pearson’s product-moment correlation ‘r’. The latter was considered as ‘high’, ‘good’, ‘fair’, or ‘weak’ when it was, respectively, ‘> 0.70’, between ‘0.50 and 0.70’, between ‘0.30 and 0.50’, or ‘≤ 0.30’ [27]. If the GLI-2021 norms [7] are valid, no ‘good’ or ‘high’ relationships should exist [28]. All mathematical computations and statistical procedures were performed using the statistical software (Statistica, version 12). Significance level was set at 0.05.

Results

Among the 1488 acquaintances of patients hospitalized at the Department of Pulmonology, Phthisiology and Allergology, 1285 (86.3%) were included in the initial stage. Non-inclusion criteria were found in 677 participants (52.7%). Among the remaining 608 participants, 127 (21.8%) failed to meet the acceptability and repeatability criteria of plethysmography/spirometry. Therefore, the final sample included 481 adults (239 males) aged between 18 and 80 years (Figure 2). Figure 3 exposes the participants’ distribution according to sex, age, and height ranges. Age distribution according to sex was similar. However, fewer adults (9.15%) were included in the age range 70.1–80.0 years. Only one female was included in the height range 1.81–1.96 m, and fewer males (2.29%) were included in the height range 1.39–1.60 m.
Figure 3.

Distribution of the 481 participants according to sex, age and height ranges.

Table 1 exposes the participants’ anthropometric data. Females and males had similar age and BMI. Compared to females, males were significantly taller and heavier, and the percentage of adults with an obesity stage-1 was significantly lower.
Table 1.

Anthropometric data of the healthy Algerian adults aged 18–80 years

 MalesFemalesTotal sample (n = 481)p-value
Sex 239 (49.69)242 (50.31)-0.847
Age(Years)47.7 ± 16.8 (45.6 to 49.8)45.1 ± 15.9 (43.1 to 47.1)46.4 ± 16.4 (44.9 to 47.9)0.079
Height(cm)173 ± 8 (172 to 174)159 ± 7 (158 to 160)166 ± 10 (165 to 167)0.001*
Weight(kg)78 ± 13 (76 to 80)68 ± 12 (66 to 69)73 ± 14 (72 to 74)0.001*
Body mass index(kg/m2)26.1 ± 4.0 (25.6 to 26.6)26.8 ± 4.3 (26.3 to 27.4)26.5 ± 4.2 (26.1 to 26.8)0.078
Corpulence statusUnderweight5 (2.09)6 (2.48)11 (2.29)0.775
Normal weight95 (39.75)82 (33.88)177 (36.80)0.182
Overweight93 (38.91)87 (35.95)180 (37.42)0.502
Obesity stage 146 (19.25)67 (27.69)113 (23.49)0.029£

Quantitative data were mean ± SD (95% confidence level). Corpulence status data were number (%). Sex was expressed as number (% of total sample).

p-value <0.05 (*Student test or 2 sided Chi-square test): males vs. females.

Anthropometric data of the healthy Algerian adults aged 18–80 years Quantitative data were mean ± SD (95% confidence level). Corpulence status data were number (%). Sex was expressed as number (% of total sample). p-value <0.05 (*Student test or 2 sided Chi-square test): males vs. females. Table 2 exposes the participants’ spirometric data. In the total sample: i) Only FEF25-75% z-score was out of the normal range; and ii) Compared to the predicted values, the measured FVC and FEF25-75% values were significantly higher. However, FEV1/FVC and FEV1 values were significantly lower.
Table 2.

Spirometric data of the healthy Algerian adults aged 18–80 years

  Males (n = 239)Females (n = 242)Total sample (n = 481)p-value
FVCMeasured (L)4.76 ± 0.94 (4.64 to 4.88)3.39 ± 0.61 (3.31 to 3.47)4.07 ± 1.05 (3.98 to 4.17)0.001*
Predicted (L)4.66 ± 0.86 (4.55 to 4.77)#3.32 ± 0.57 (3.25 to 3.39)#3.99 ± 0.99 (3.90 to 4.08)#0.001*
% Predicted103 ± 12 (101 to 104)102 ± 12 (101 to 104)103 ± 12 (101 to 104)0.877
z-score0.18 ± 0.91 (0.06 to 0.30)0.16 ± 0.87 (0.05 to 0.26)0.17 ± 0.89 (0.09 to 0.25)0.763
FEV1Measured (L)3.71 ± 0.78 (3.61 to 3.81)2.68 ± 0.54 (2.67 to 2.80)3.19 ± 0.84 (3.11 to 3.27)0.001*
Predicted (L)3.74 ± 0.77 (3.64 to 3.84)2.73 ± 0.54 (2.61 to 2.75)#3.23 ± 0.83 (3.16 to 3.31)#0.001*
% Predicted100 ± 13 (98 to 101)99 ± 12 (97 to 100)99 ± 12 (98 to 100)0.248
z-score−0.02 ± 0.92 (−0.14 to 0.10)−0.13 ± 0.88 (−0.24 to −0.02)−0.07 ± 0.90 (−0.15 to 0.01)0.197
FEV1/FVCCalculated (AV)0.78 ± 0.05 (0.77 to 0.78)0.79 ± 0.05 (0.78 to 0.80)0.78 ± 0.05 (0.78 to 0.79)0.019*
Predicted (AV)0.80 ± 0.03 (0.80 to 0.81)#0.82 ± 0.03 (0.82 to 0.83)#0.81 ± 0.03 (0.81 to 0.82)#0.001*
% Predicted97 ± 6 (96 to 98)96 ± 6 (95 to 97)96 ± 6 (96 to 97)0.021
z-score−0.34 ± 0.74 (−0.43 to −0.24)−0.50 ± 0.70 (−0.59 to −0.41)−0.42 ± 0.72 (−0.48 to −0.35)0.013*
FEF25-75%Measured (L/s)4.71 ± 1.10 (4.57 to 4.85)3.41 ± 0.74 (3.32 to 3.50)4.06 ± 1.14 (3.95 to 4.16)0.001*
Predicted (L/s)3.53 ± 1.01 (3.40 to 3.65)#2.86 ± 0.76 (2.77 to 2.96)#3.19 ± 0.95 (3.11 to 3.28)#0.001*
% Predicted140 ± 37 (136 to 145)124 ± 29 (120 to 128)132 ± 34 (129 to 135)0.000
z-score1.01 ± 0.80 (0.91 to 1.12)0.65 ± 0.76(0.55 to 0.74)0.83 ± 0.80 (0.76 to 0.90)0.001*

AV: absolute value. FVC: forced vital capacity. FEF25-75%: forced expiratory flow at 25–75% of FVC. FEV1: forced expiratory volume in 1 second.

Data were mean ± SD (95% confidence level).

*p-value <0.05 (Student test): males vs. females.

#p-value <0.05 (Wilcoxon test): determined value vs. predicted value.

Spirometric data of the healthy Algerian adults aged 18–80 years AV: absolute value. FVC: forced vital capacity. FEF25-75%: forced expiratory flow at 25–75% of FVC. FEV1: forced expiratory volume in 1 second. Data were mean ± SD (95% confidence level). *p-value <0.05 (Student test): males vs. females. #p-value <0.05 (Wilcoxon test): determined value vs. predicted value. Table 3 exposes the participants’ SLVs. In the total sample: The mean z-scores of FRC, RV, and RV/TLC were out of the normal range; All the determined SLVs were significantly different from those predicted from the GLI-2021 norms. They were lower than the predicted values for SVC and IC, and higher than the predicted values for FRC, RV, TLC, ERV, and RV/TLC; and iii) The means (in mL) of ∆SVC, ∆IC, ∆ERV, and ∆TLC were not ‘clinically’ significant (=- 100; −170, 170, and 240, respectively), but ∆RV and ∆FRC were ‘clinically’ significant (=370, and 480, respectively).
Table 3.

Static lung volumes of healthy Algerian adults aged 18–80 years

  Males (n = 239)Females (n = 242)Total sample (n = 481)p-value
SVCMeasured (L)4.82 ± 0.89 (4.71 to 4.94)3.39 ± 0.59 (3.32 to 3.47)4.10 ± 1.04 (4.01 to 4.20)0.001*
Predicted (L)4.90 ± 0.78 (4.80 to 5.00)#3.51 ± 0.55 (3.44 to 3.58)#4.20 ± 0.97 (4.11 to 4.29#0.001*
∆ (L)−0.08 ± 0.57 (−0.16 to −0.01)−0.11 ± 0.40 (−0.16 to −0.06)−0.10 ± 0.49 (−0.14 to −0.05)0.505
% Predicted99 ± 12 (97 to 100)97 ± 11 (96 to 99)98 ± 12 (97 to 99)0.177
z-score−0.12 ± 0.97 (−0.24 to 0.01)−0.23 ± 0.92 (−0.35 to −0.11)−0.17 ± 0.94 (−0.26 to-0.09)0.194
FRCMeasured (L)3.81 ± 0.64 (3.73 to 3.89)2.88 ± 0.44 (2.83 to 2.94)3.34 ± 0.72 (3.28 to 3.41)0.001*
Predicted (L)3.24 ± 0.37 (3.19 to 3.28)#2.49 ± 0.25 (2.45 to 2.52)#2.86 ± 0.49 (2.82 to 2.90)#0.001*
∆ (L)0.57 ± 0.54 (0.50 to 0.64)0.40 ± 0.35 (0.45 to 0.39)0.48 ± 0.48 (0.44 to 0.53)0.001*
% Predicted118 ± 17 (116 to 120)116 ± 16 (114 to 118)117 ± 17 (116 to 119)0.231
z-score0.76 ± 0.73 (0.67 to 0.86)0.74 ± 0.72 (0.65 to 0.83)0.75 ± 0.72 (0.69 to 0.82)0.680
RVCalculated (L)2.15 ± 0.50 (2.09 to 2.22)1.73 ± 0.35 (1.68 to 1.77)1.94 ± 0.48 (1.90 to 1.98)0.001*
Predicted (L)1.78 ± 0.32 (1.74 to 1.82)#1.36 ± 0.23 (1.33 to 1.39)#1.57 ± 0.35 (1.54 to 1.60)#0.001*
∆ (L)0.38 ± 0.41 (0.33 to 0.43)0.37 ± 0.33 (0.40 to 0.26)0.37 ± 0.34 (0.34 to 0.40)0.777
% Predicted122 ± 24 (119 to 125)128 ± 20 (125 to 130)125 ± 22 (123 to 127)0.004*
z-score0.68 ± 0.73 (0.59 to 0.78)0.79 ± 0.58 (0.72 to 0.87)0.74 ± 0.66 (0.68 to 0.80)0.073
TLCCalculated (L)6.92 ± 0.95 (6.80 to 7.04)5.11 ± 0.63 (5.03 to 5.19)6.01 ± 1.21 (5.90 to 6.12)0.001*
Predicted (L)6.68 ± 0.72 (6.59 to 6.78)#4.87 ± 0.49 (4.81 to 4.93)#5.77 ± 1.10 (5.67 to 5.87)#0.001*
∆ (L)0.24 ± 0.72 (0.15 to 0.33)0.24 ± 0.18 (0.30 to 0.49)0.24 ± 0.62 (0.18 to 0.29)0.969
% Predicted104 ± 11 (102 to 105)105 ± 10 (104 to 106)104 ± 11 (104 to 105)0.186
z-score0.31 ± 0.90 (0.19 to 0.42)0.39 ± 0.82 (0.28 to 0.49)0.35 ± 0.86 (0.27 to 0.42)0.311
ERVMeasured (L)1.62 ± 0.61 (1.55 to 1.70)1.13 ± 0.42 (1.08 to 1.19)1.38 ± 0.58 (1.32 to 1.43)0.001*
Predicted (L)1.39 ± 0.36 (1.34 to 1.43)#1.02 ± 0.28 (0.99 to 1.06)#1.20 ± 0.37 (1.17 to 1.24)#0.001*
∆ (L)0.24 ± 0.46 (0.18 to 0.30)0.11 ± 0.07 (0.15 to 0.33)0.17 ± 0.40 (0.14 to 0.21)0.001*
% Predicted117 ± 34 (113 to 122)112 ± 37 (107 to 117)115 ± 36 (112 to 118)0.101
z-score0.36 ± 0.75 (0.27 to 0.46)0.23 ± 0.79 (0.12 to 0.33)0.29 ± 0.77 (0.22 to 0.36)0.052
ICCalculated (L)3.20 ± 0.60 (3.12 to 3.28)2.26 ± 0.43 (2.21 to 2.32)2.73 ± 0.70 (2.67 to 2.79)0.001*
Predicted (L)3.43 ± 0.48 (3.37 to 3.50)#2.37 ± 0.28 (2.34 to 2.41)#2.90 ± 0.66 (2.84 to 2.96)#0.001*
∆ (L)−0.23 ± 0.54 (−0.30 to −0.17)−0.11±-0.16 (−0.06 to 0.39)−0.17 ± 0.47 (−0.21 to −0.13)0.003*
% Predicted94 ± 16 (92 to 96)96 ± 16 (94 to 98)95 ± 16 (93 to 96)0.188
z-score−0.35 ± 0.91 (−0.47 to −0.23)−0.23 ± 0.86 (−0.34 to −0.12)−0.29 ± 0.88 (−0.37 to −0.21)0.126
RV/TLCCalculated (%)31.22 ± 6.94 (30.34 to 32.10)34.04 ± 6.70 (33.19 to 34.89)32.64 ± 6.96 (32.01 to 33.26)0.001*
Predicted (%)26.64 ± 5.69 (25.91 to 27.36) #28.06 ± 5.99 (27.30 to 28.82) #27.35 ± 5.88 (26.83 to 27.88) #0.001*
∆ (%)4.58 ± 4.51 (4.01 to 5.16)5.98 ± 5.46 (6.50 to 4.13)5.28 ± 4.38 (4.89 to 5.68)0.001*
% Predicted119 ± 20 (116 to 121)123 ± 16 (121 to 125)121 ± 18 (119 to 122)0.023*
z-score0.78 ± 0.86 (0.67 to 0.89)0.88 ± 0.62 (0.80 to 0.95)0.83 ± 0.75 (0.76 to 0.90)0.172

ERV: expiratory reserve volume. FRC: functional residual capacity. IC: inspiratory capacity. RV: residual volume. SVC: slow vital capacity. TLC: total lung capacity.

∆ = determined value minus predicted value.

Data were mean ± SD (95% confidence level).

*p-value <0.05 (Student test): males vs. females.

p-value <0.05 (Wilcoxon test): determined value vs. predicted value.

Static lung volumes of healthy Algerian adults aged 18–80 years ERV: expiratory reserve volume. FRC: functional residual capacity. IC: inspiratory capacity. RV: residual volume. SVC: slow vital capacity. TLC: total lung capacity. ∆ = determined value minus predicted value. Data were mean ± SD (95% confidence level). *p-value <0.05 (Student test): males vs. females. p-value <0.05 (Wilcoxon test): determined value vs. predicted value. Figure 4 illustrates the Bland and Altman comparisons between measured and predicted SLVs from the GLI-2021 norms. There was a systematic bias between the measured and predicted values for all measured SLVs (Table 3 and Figure 4). The correlations between mean differences and mean values were significant for all the SLVs, and were ‘good’ for FRC (Figure 4B) and ERV (Figure 4E), ‘fair’ for RV (Figure 4C), and ‘weak’ for SVC (Figure 4A), TLC (Figure 4D), and IC (Figure 4F).
Figure 4.

Bland and Altman representation of measured and predicted static lung volumes determined from the 2021-GLI (n = 481).

Bland and Altman representation of measured and predicted static lung volumes determined from the 2021-GLI (n = 481). Table 4 exposes the percentages of participants having abnormal SLVs. In the total sample, more than 5% of adults had ‘clinically’ lower SVC (6.3%), and IC (5.82%), and ‘clinically’ higher FRC (10.60%), RV/TLC (9.36%), and RV (6.24%).
Table 4.

Percentages of healthy Algerian adults having abnormal static lung volumes (SLVs)

 
SLV z-score < −1.645
SLV z-score > + 1.645
 Males (n = 239)Females (n = 242)Total sample (n = 481)Males (n = 239)Females (n = 242)Total sample (n = 481)
SVC4.607.44*6.03*3.772.072.91
FRC0.000.000.0011.72*9.50*10.60*
RV0.000.410.217.53*4.966.24*
TLC1.260.410.837.53*4.135.82*
ERV0.000.830.425.44*4.134.78
IC7.11*4.555.82*1.261.241.25
RV/TLC0.000.410.2110.46*8.26*9.36*

ERV: expiratory reserve volume. FRC: functional residual capacity. IC: inspiratory capacity. RV: residual volume. SVC: slow vital capacity. TLC: total lung capacity.

*Percentage > 5.00%.

Percentages of healthy Algerian adults having abnormal static lung volumes (SLVs) ERV: expiratory reserve volume. FRC: functional residual capacity. IC: inspiratory capacity. RV: residual volume. SVC: slow vital capacity. TLC: total lung capacity. *Percentage > 5.00%. The z-scores of SLVs were not related to sex (Table 3). Table 5 exposes the ‘r’ between SLVs z-scores and anthropometric data. In the total sample: i) ‘Weak or no correlations’ were noted between SLVs, and both age and height; and ii) ‘Fair’ correlations were noted between weight or BMI, and FRC or ERV.
Table 5.

Pearson correlation coefficient (r) between the static lung volumes z-scores and the anthropometric data

  SVCFRCRVTLCERVICRV/TLC
Totalsample(n = 481)Age (Year)0.0862d0.0525d−0.0256d0.0826d−0.0541d0.1193d*−0.0598d
Height (cm)−0.0572d−0.1172d*−0.1188d*−0.1641d*0.0318d−0.1757d*−0.0465d
Weight (kg)−0.1222d*−0.3911c*−0.1198d*−0.1716d*−0.3227c*0.0904d*−0.0227d
BMI (kg/m2)−0.1037d*−0.3671c*−0.0469d*−0.0767d*−0.4085c*0.2391d*0.0132d
Males(n = 239)Age (Year)0.0212d0.0132d0.0170d0.0421d−0.1246d0.1494d*0.0157d
Height (cm)−0.1164d−0.1625d*−0.1339d*−0.1748d*−0.0160d−0.2259d*−0.0676d
Weight (kg)−0.2176d*−0.4516c*−0.1276d*−0.2238d*−0.3517d*0.0262d−0.0054d
BMI (kg/m2)−0.1874d*−0.4041c*−0.0631d−0.1592d*−0.3769c*0.1448d0.0426d
Females(n = 242)Age (Year)0.1492d*0.0915d−0.0666d0.1383d*0.0003 d0.0993d−0.1590d*
Height (cm)−0.1497d*−0.1913d*−0.0187d−0.1836d*−0.0613 d−0.1124d0.0915d
Weight (kg)−0.0844d−0.4079c*−0.0527d−0.0957d−0.4269c*0.2458d*0.0112d
BMI (kg/m2)−0.0154d−0.3336c*−0.0477d−0.0027d−0.4277c*0.3223c*−0.0345d

BMI: body mass index. ERV: expiratory reserve volume. FRC: functional residual capacity. IC: inspiratory capacity. RV: residual volume. SVC: slow vital capacity. TLC: total lung capacity.

*Probability < 0.05.

Pearson r: aHigh (r > 0.70), bGood (r between 0.50–0.70), cFair (r between 0.30–0.50); dWeak or no association (r < 0.30).

Pearson correlation coefficient (r) between the static lung volumes z-scores and the anthropometric data BMI: body mass index. ERV: expiratory reserve volume. FRC: functional residual capacity. IC: inspiratory capacity. RV: residual volume. SVC: slow vital capacity. TLC: total lung capacity. *Probability < 0.05. Pearson r: aHigh (r > 0.70), bGood (r between 0.50–0.70), cFair (r between 0.30–0.50); dWeak or no association (r < 0.30).

Discussion

The results of this study, performed in an Algerian population of 481 healthy non-smoking adults, are mixed. On the one hand, the GLI-2021 norms fit well to SVC, TLC, ERV and IC. On the other hand, they do not fit to FRC, RV, and RV/TLC. To the best of the authors’ knowledge, no previous study has aimed at evaluating the validity of the GLI-2021 norms in healthy adult populations. Accurate norms of SLVs have several factors of primary care significance. First, TLC allows more meaningful interpretations of FEV1 and FVC [1]. Second, the determination of TLC LLN facilitates accurate diagnosis of the restrictive ventilatory defect (i.e. TLC < LLN) [1]. Third, a reduced TLC (e.g. TLC < LLN) correlates with both morbidity and mortality, quality of life, and physical activity [29,30]. Fourth, the determination of RV ULN or IC LLN eases the correct diagnosis of lung-hyperinflation (i.e. RV > ULN or IC < LLN) [26]. Fifth, SLVs provide a physiological pattern, which can be used in combination with spirometry and transfer factor of the lung for carbon monoxide tests to refine a differential diagnosis [1,7]. By developing sex-specific norms that summarize the height- and age-related changes in SLV data, the GLI-2021 norms should improve the interpretation of SLVs values [7].

Discussion of the methodology

One of the main strong points of this study is its prospective design. However, it would have been better if more than one centre was included. According to the GLI Task Force [31], at least 300 participants (150 males) are required to validate norms and to avoid spurious variances due to sampling mistakes. This requirement was largely considered in this study (239 males and 242 females). The population from which the norms are derived should be representative of the general population [28]. Age scattering and other anthropometric, ethnic, socioeconomic, and environmental factors should be equivalent since such factors can mark lung function [28]. Furthermore, the methodology for performing plethysmographic tests (eg; protocol and equipment) must be stringent [1]. In order to avoid biased assessment of outcomes [32] and sex-related effect on lung function [33], similar percentages of males and females were included in this study (Table 1). The present study included adults with large age range (18–80 years) and height range (149–196 cm for males, and 139–181 cm for females), and with obesity stage-1 in 23.49% of them. The present study height range was closer to the one reported by Hall et al. [7], where the height ranges were 145–203 cm, and 134–186 cm, respectively, in males and females. The percentage of Algerian adults with overweight or obesity (60.9%) was closer to that reported in the GLI-2021 study (i.e. 54.8%) [7]. Moreover, since 30% of Algerian adults have obesity [34], the present study group composition reflected this ‘healthy’ population as it exists in real life. It would have been better if overweight and obese individuals were excluded in order to represent ‘ideal’ health and to allow assessment of the impact of weight on SLVs [7]. However, the aforementioned strategy dismisses a significant fraction of participants with no documented evidence of lung condition [7]. The above point was largely discussed by Hall et al. [7]. Similar to the study generating the GLI-2021 SLVs norms [7], where healthy participants were never-smokers with no history of self-reported or physician-diagnosed respiratory condition, in the present study, only healthy never-smokers were included. The external validity of this study was therefore increased. Unlike the study generating the GLI-2021 SLVs norms [7], where different body plethysmography and gas dilution techniques were used, in this study, only one plethysmograph was used, which ensures more intern validity for the reported data. It is important to highlight that the SLVs collected for the two gas dilution techniques (eg; nitrogen washout and helium dilution) and body plethysmography demonstrate remarkable overlap [7]. As recommended, and as done in the studies retained to generate SLVs norms [7], the American thoracic society and the European respiratory society guidelines for spirometry and plethysmography [17,18] were applied. We applied the same statistical type of analysis used in previous similar North African studies [8,10], aiming to ascertain how well do the GLI-2012 norms [6] fit contemporary North African spirometric data. However, the suggested ‘fairly’ high cut-point of ‘0.5’ for a significant mean difference to the GLI-2021 norms [approximately equating to a change of 10% for FRC, 8% for IC, 8% for TLC (in older adults), 5% for TLC (in adults aged 30– 50 years), and 30% for ERV and RV (older adults) [7]] requires to be further assessed for its relevance in clinical medicine, as well as in epidemiological studies. Moreover, the relationships between z-scores and age, height, weight, BMI, and sex were examined. The presence of any such relationship was in favour of the non-validity of the GLI-2021 norms.

How well did the GLI-2012 norms fit contemporary Algerian spirometric data?

Our results related to spirometric data confirm our previous conclusion [10] that GLI-2012 norms [6] are valid to interpret FEV1, FVC, and FEV1/FVC but not FEF25-75%. This point was largely discussed [10].

How well did the GLI-2021 norms fit contemporary Algerian SLVs data?

According to the GLI Task Force, data from ‘non-European’ ancestries, eg the Arab World, are urgently required to allow the expansion of the GLI-2021 norms [7] to the global population. Our results demonstrate that the application of GLI-2021 norms [7] to a contemporary Algerian population provides mixed results. First, it ‘appears’ that the GLI-2021 norms [7] fit well to SVC, IC, ERV, and TLC in Algerian adults. On the one hand, the above data mean z-scores were in the normal range (Table 3), and their observed variability (SD of the z-score) was close to one (Table 3), indicating a good overall fit of the GLI-2021 norms [7]. On the other hand, the means of ∆SVC, ∆IC, ∆ERV, and ∆TLC were not ‘clinically’ significant (Table 3), and more than 5% of the total sample had ‘clinically’ lower SVC and IC (Table 4). Secondly, it is clear that the GLI-2021 norms [7] do not fit to FRC, RV, and RV/TLC in Algerian adults. The above data mean z-scores were out of the normal range (Table 3), the means of ∆FRC and RV were ‘clinically’ significant (Table 3), and more than 5% of the total sample had ‘clinically’ higher FRC, RV, and RV/TLC (Table 4). In this study, no SLV z-score was related to sex (Table 3), and there were ‘fair’ significant correlations only between weight or BMI, and both ERV and FRC (Table 5). These results support the use of the GLI-2021 norms [7] to interpret SVC, IC, ERV, and TLC data in the Algerian adult population.

Why did the GLI-2021 norms fit perfectly well contemporary Algerian SVC, TLC, ERV, and IC data?

The GLI-2021 datasets [7] were obtained from 17 centers in 33 countries, including Tunisia. Although representing only 8.55% of the total sample data, the inclusion of Tunisians could partially explain why the GLI-2021 norms [7] fit contemporary Algerian SVC, TLC, ERV, and IC data.

Why didn’t the GLI-2021 norms fit contemporary Algerian FRC, RV, and RV/TLC data?

Four explanations could be advanced. The first is related to the impact of ethnicity on LFPs [35]. In fact, the great majority (>90%) of the observations included in the GLI-2021 norms [7] came from individuals having a ‘European’ ancestry. This point was clearly foreseen by the GLI Task Force noting that the derived GLI-2021 norms may not be appropriate for individuals of ‘non-European’ ancestry [7]. The second explanation is related to the effects of parity on SLVs [4,14]. A previous Algerian study [14] reported that compared to females with a parity ≤ 6, those with a parity > 6 had higher FRC and RV. Moreover, compared to females with a parity ≤ 4, those with a parity > 9 had higher RV. The third explanation is linked to the effects of obesity on SLVs [4,36,37]. In our study, 60.9% of adults were overweight or obese, and BMI was negatively associated with some SLVs (e.g. the ‘r’ between BMI and FRC was significant at −0.33). BMI gain causes an accelerated decline in LFPs [38], and induces a decrease in FRC [4,36,37]. Moreover, reduced FRC or RV has been described in overweight and obese individuals [39]. In the GLI-2021 study [7], overweight and obese adults had lower FRC z-scores. However, it is necessary to relativize our findings. In fact, in the GLI-2021 study [7], the FRC coefficient of variation was 20%, which is comparable to a range of normal of 60–140%, much wider than the commonly used threshold of 80–120%. Therefore, if the 140% threshold is applied as an ULN, the percentage of Algerian with higher FRC diminishes from 10.60% (FRC z-score > + 1.645, Table 4) to 8.52%. The fourth hypothesis is related to the technique(s) applied for FRC measurements (ie; plethysmography (this study) vs. plethysmography and gas dilution (GLI-2021) [7]). On the one hand, it is recognized that individual SLVs, measured by gas dilution and the plethysmography technique are not exchangeable [18]. On the other hand, GLI-2021 primary analyses of the FRC values reported significant overlap between plethysmography and gas dilution techniques across all ages [7]. In the GLI-2021 study [7], the relative differences in FRC between plethysmography and gas dilution techniques were < 120 mL, which were within the limits of technical precision [18].

Study limitations

This study presented three limitations. The first concerns the rational of the study itself. According to the GLI Task Force [7], SLVs norms are limited to people of ‘European’ ancestry. As these different ethnic/racial groups do not appear to have LFPs that fit the same prediction formulae [35], it is ‘irrational’ to compare the Algerian SLVs data with those of individuals of a ‘European’ ancestry. However, taking into consideration, that Tunisia participated in the GLI-2021 study [7], and that both Tunisian and Algerian populations have similar ethnic backgrounds, the study becomes ‘rational’. Like Tunisians, Algerians are mainly genetically descendants of native Berber groups, with some Punic and Middle Eastern input [40,41]. To a lesser degree, Algerians are descendants of other North-African and/or European people [40,41]. Nowadays, the approach to compute the normal values using cross-sectional reference equations that include terms for ethnicity/race is of uncertain clinical benefit and may highlight inequalities [42]. It appears that there is no evidence that ethnic/race-based spirometry norms improved the prediction of clinical events compared to ethnic/race-neutral norms [42]. Therefore, the inclusion of ethnicity/race in spirometry norms should be reconsidered [42]. The second limitation is related to the convenience sampling whose primary weaknesses are the hazard that the sample might not characterize the population as a whole, and the results might propose a bias in the answers from volunteers [43]. On the one hand, due to our atypical method of inclusion, our results cannot be generalized to the target population because of the likely bias of the sampling procedure due to under-representation of subgroups in the sample in comparison to the population of interest. On the other hand, our convenience sampling is characterized with unsatisfactory power to recognize differences of population subcategories [44]. However, the convenience sampling is the most often used due to the numerous advantages it provides: method extremely speedy, easy, readily available, and cost-effective [43]. The third limitation concerns the non-determination of the individuals’ socioeconomic levels and/or occupational status. However, this omission might not have influenced the results, since there were no significant differences in some SLVs (eg; SVC, FRC, TLC, and RV) depending on the general socioeconomic status [4].

Recommendations

First, since the GLI data repository accepts additional datasets from individuals of ‘non-European’ ancestry, Algerian SLVs data will be submitted to that repository. Second, in order to simplify comparative studies between countries, and to avoid mistakes due to age-related gaps in norms [45], the authors acclaim the implementation of the GLI-2021 norms [7] in healthcare in Algeria. However, as recommended by the GLI Task Force, if GLI-2021 norms [7] are applied to Algerians, this should be clearly stated to ensure that results are not misinterpreted. To conclude, our results, related to the validity of the GLI-2021 norms [7] in healthy Algerian adults, are mixed. They fit well to SVC, TLC, ERV, and IC, but they do not fit to FRC, RV, and RV/TLC. However, although imperfect, the authors support the use of the GLI-2021 norms [7] to interpret clinical and research results in contemporary Algerian adults.
  39 in total

1.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

Review 2.  In the clinic: obesity.

Authors:  Adam Gilden Tsai; Thomas A Wadden
Journal:  Ann Intern Med       Date:  2013-09-03       Impact factor: 25.391

3.  Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry.

Authors:  Graham L Hall; Nicole Filipow; Gregg Ruppel; Tolu Okitika; Bruce Thompson; Jane Kirkby; Irene Steenbruggen; Brendan G Cooper; Sanja Stanojevic
Journal:  Eur Respir J       Date:  2021-03-11       Impact factor: 16.671

4.  The Global Lung Initiative 2012 reference values reflect contemporary Australasian spirometry.

Authors:  Graham L Hall; Bruce R Thompson; Sanja Stanojevic; Michael J Abramson; Richard Beasley; Andrew Coates; Annette Dent; Brenton Eckert; Alan James; Sue Filsell; A W Bill Musk; Gary Nolan; Barbara Dixon; Chris O'Dea; Jenni Savage; Janet Stocks; Maureen P Swanney
Journal:  Respirology       Date:  2012-10       Impact factor: 6.424

5.  Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients.

Authors:  Martin R Miller; Philip H Quanjer; Maureen P Swanney; Gregg Ruppel; Paul L Enright
Journal:  Chest       Date:  2010-06-03       Impact factor: 9.410

6.  Sampling in Developmental Science: Situations, Shortcomings, Solutions, and Standards.

Authors:  Marc H Bornstein; Justin Jager; Diane L Putnick
Journal:  Dev Rev       Date:  2013-12

7.  Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Benjamin Waschki; Anne M Kirsten; Olaf Holz; Kai-Christian Mueller; Miriam Schaper; Anna-Lena Sack; Thorsten Meyer; Klaus F Rabe; Helgo Magnussen; Henrik Watz
Journal:  Am J Respir Crit Care Med       Date:  2015-08-01       Impact factor: 21.405

8.  Evaluation of the global lung function initiative 2012 reference values for spirometry in a Swedish population sample.

Authors:  Helena Backman; Anne Lindberg; Anssi Sovijärvi; Kjell Larsson; Bo Lundbäck; Eva Rönmark
Journal:  BMC Pulm Med       Date:  2015-03-25       Impact factor: 3.317

9.  Defining and grading an obstructive ventilatory defect (OVD): 'FEV1/FVC lower limit of normal (LLN) vs. Z-score' and 'FEV1 percentage predicted (%pred) vs. Z-score'.

Authors:  Rim Kammoun; Ines Ghannouchi; Sonia Rouatbi; Helmi Ben Saad
Journal:  Libyan J Med       Date:  2018-12       Impact factor: 1.743

10.  [The importance of lung volumes in the investigation of heavy smokers].

Authors:  H Ben Saad; L Ben Amor; S Ben Mdalla; I Ghannouchi; M Ben Essghair; R Sfaxi; A Garrouche; N Rouatbi; S Rouatbi
Journal:  Rev Mal Respir       Date:  2013-07-20       Impact factor: 0.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.